Prevalence, Severity, and Symptom Bother of Lower Urinary Tract Symptoms among Men in the EPIC Study: Impact of Overactive Bladder

European Urology

Volumn 56, Issue 1, 2009, Pages 14-20

  Irwin, Debra E ^a   Milsom, Ian ^b   Kopp, Zoe ^c   Abrams, Paul ^d   Artibani, Walter ^e   Herschorn, Sender ^f  

^a IL   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c PFIZER INC   (United States)

^d SOUTHMEAD HOSPITAL   (United Kingdom)

^e UNIVERSITY OF PADOVA   (Italy)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Men; Overactive bladder; Prevalence; Severity; Urination disorders

Indexed keywords

ADULT; ARTICLE; DISEASE SEVERITY; GALLBLADDER EMPTYING; GROUPS BY AGE; HEALTH SURVEY; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MICTURITION; NOCTURIA; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; POPULATION; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; SCORING SYSTEM; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE;

ADULT; AGE DISTRIBUTION; AGED; COMORBIDITY; CROSS-SECTIONAL STUDIES; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PREVALENCE; SEVERITY OF ILLNESS INDEX; URINARY BLADDER, OVERACTIVE; URINATION DISORDERS; UROLOGIC DISEASES;

EID: 67349125471     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.02.026     Document Type: Article

References (28)

1. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21 (2002) 167-178
2. Abrams P., Artibani W., Cardozo L., et al. Reviewing the ICS 2002 Terminology Report: the ongoing debate. Neurourol Urodyn 25 (2006) 293
3. Peters T.J., Donovan J.L., Kay H.E., et al. The International Continence Society "Benign Prostatic Hyperplasia" Study: the bothersomeness of urinary symptoms. J Urol 157 (1997) 885-889
4. Abdel-Aziz K.F., and Lemack G.E. Overactive bladder in the male patient: bladder, outlet, or both?. Curr Urol Rep 3 (2002) 445-451
5. Chapple C.R., and Roehrborn C.G. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 49 (2006) 651-659
6. Andersson S.O., Rashidkhani B., Karlberg L., Wolk A., and Johansson J.E. Prevalence of lower urinary tract symptoms in men aged 45-79 yr: a population-based study of 40 000 Swedish men. BJU Int 94 (2004) 327-331
7. Irwin D.E., Milsom I., Hunskaar S., et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50 (2006) 1306-1315
8. Barry M.J., Fowler Jr. F.J., O'Leary M.P., et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148 (1992) 1549-1557
9. Boyle P., Robertson C., Mazzetta C., et al. The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study. BJU Int 92 (2003) 409-414
10. Seim A., Hoyo C., Ostbye T., and Vatten L. The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study. BJU Int 96 (2005) 88-92
11. Irwin D.E., Abrams P., Milsom I., Kopp Z., and Reilly K. Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU Int 101 (2008) 1381-1387
12. Irwin D.E., Milsom I., Kopp Z., and Abrams P. Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol 53 (2008) 1029-1039
13. Coyne K.S., Zyczynski T., Margolis M.K., Elinoff V., and Roberts R.G. Validation of an overactive bladder awareness tool for use in primary care settings. Adv Ther 22 (2005) 381-394
14. Coyne K.S., Matza L.S., Kopp Z., and Abrams P. The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 49 (2006) 1079-1086
15. Coyne K.S., Zhou Z., Bhattacharyya S.K., et al. The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int 92 (2003) 948-954
16. Haidinger G., Madersbacher S., Waldhoer T., Lunglmayr G., and Vutuc C. The prevalence of lower urinary tract symptoms in Austrian males and associations with sociodemographic variables. Eur J Epidemiol 15 (1999) 717-722
17. Rosen R., Altwein J., Boyle P., et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44 (2003) 637-649
18. Sladden M.J., Hughes A.M., Hirst G.H., and Ward J.E. A community study of lower urinary tract symptoms in older men in Sydney, Australia. Aust N Z J Surg 70 (2000) 322-328
19. Milsom I., Abrams P., Cardozo L., et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87 (2001) 760-766
20. Stewart W.F., Van Rooyen J.B., Cundiff G.W., et al. Prevalence and burden of overactive bladder in the United States. World J Urol 20 (2003) 327-336
21. Tikkinen K.A., Tammela T.L., Rissanen A.M., Valpas A., Huhtala H., and Auvinen A. Is the prevalence of overactive bladder overestimated? A population-based study in Finland. PLoS One 2 (2007) e195
22. Abrams P., Avery K., Gardener N., and Donovan J. The International Consultation on Incontinence Modular Questionnaire: www.iciq.net. J Urol 175 (2006) 1063-1066 discussion 1066
23. De Nunzio C., Franco G., Rocchegiani A., et al. The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. J Urol 169 (2003) 535-539
24. MacDiarmid S.A., Peters K.M., Chen A., et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc 83 (2008) 1002-1010
25. Kaplan S.A., Roehrborn C.G., Rovner E.S., et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296 (2006) 2319-2328
26. Kaplan S.A., Roehrborn C.G., Chancellor M., et al. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU Int 102 (2008) 1133-1139
27. Rovner E.S., Kreder K., Sussman D.O., et al. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol 180 (2008) 1034-1041
28. Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol. In press. doi:10.1016/j.eururo.2008.11.026.